Vasopeptidase inhibitors: A new therapeutic concept in cardiovascular disease?

Circulation

Volumn 104, Issue 15, 2001, Pages 1856-1862

  Corti, Roberto ^a   Burnett Jr, John C ^b   Rouleau, Jean L ^c   Ruschitzka, Frank ^a   Lüscher, Thomas F ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b MAYO CLINIC   (United States)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Heart failure; Hypertension; Treatment

Indexed keywords

ADRENOMEDULLIN; ANGIOTENSIN; ATRIAL NATRIURETIC FACTOR; BRADYKININ; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NATRIURETIC PEPTIDE TYPE C; NITRIC OXIDE; VASOPEPTIDASE INHIBITOR;

ARTICLE; BLOOD FLOW; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; FLUID BALANCE; HEART FAILURE; HUMAN; HYPERTENSION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SECRETION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VASCULAR RESISTANCE; VASOCONSTRICTION; VASODILATATION;

EID: 0035834159     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/hc4001.097191     Document Type: Article

References (50)

1. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor
2. ACE inhibitors promote nitric oxide accumulation to modulate myocardial oxygen consumption
3. Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endotheliumderived bradykinin
4. Antihypertensive therapy prevents endothelial dysfunction in chronic nitric oxide deficiency: Effect of verapamil and trandolapril
5. Local production of kinins contributes to the endothelium dependent relaxations evoked by converting enzyme inhibitors in isolated arteries
6. Vasopeptidase inhibition exhibits endothelial protection in salt-induced hypertension
7. Comparison of effects of angiotensin I-converting enzyme inhibition and β-blockade for 2 years on function of small arteries from hypertensive patients
8. Contrasting effect of antihypertensive treatment on the renal response to L-arginine
9. Effect of captopril and enalapril on endothelial function in hypertensive patients
10. Effects of cilazapril on vascular structure and function in essential hypertension
11. Effects of angiotensin converting enzyme inhibition on endothelium-dependent vasodilatation in essential hypertensive patients
12. Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure
13. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: The TREND (Trial on Reversing ENdothelial Dysfunction) Study
14. The kallikrein-kininogen-kinin system: Lesson from the quantification of endogenous kinins
15. Summary of randomized trials of angiotensin converting enzyme inhibitors
16. Effects of an angiotensin-convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
17. Effects of synthetic atrial natriurefic factor on renal function and renin release
18. Potentiation of natriuretic peptides by neutral endopeptidase inhibitors
19. Sympathetic responses to atrial natriuretic peptide in patients with congestive heart failure
20. Atrial natriuretic peptide elevation in congestive heart failure in the human
21. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure
22. The role of neutral endopeptidase in dogs with evolving congestive heart failure
23. Neutral endopeptidase inhibition potentiates the natriuretic actions of adrenomedullin
24. Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo
25. Comparison of candoxatril and atrial natriuretic factor in healthy men: Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin
26. Protective effect of omapatrilat, a vasopeptidase inhibitor, on the metabolism of bradykinin in normal and failing human hearts
27. Neutral endopeptidase and angiotensin-converting enzyme inhibitors increase nitric oxide production in isolated canine coronary microvessels by a kinin-dependent mechanism
28. Chronic inhibition of endopeptidase 24.11 in essential hypertension: Evidence for enhanced atrial natriuretic peptide and angiotensin II
29. Renal response to candoxatrilat in patients with heart failure
30. Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus
31. Effects of omapatrilat in low, normal, and high renin experimental hypertension
32. Vasopeptidase inhibition has potent effects on blood pressure and resistance arteries in stroke-prone spontaneously hypertensive rats
33. Vasopeptidase inhibition prevents endothelial dysfunction of resistance arteries in salt-sensitive hypertension in comparison with single ACE inhibition
34. Randomized double-blind comparison of omapatrilat with amlodipine in mild-to-moderate hypertension
35. Omapatrilat compared with lisinopril in treatment of hypertension as assessed by ambulatory blood pressure monitoring
36. Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension
37. Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects
38. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure
39. Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril
40. Endogenous natriuretic peptides participate in the renal and humoral actions of acute vasopeptidase inhibition in experimental mild heart failure
41. The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure
42. Long-term beneficial hemodynamic and neurohormonal effects of vasopeptidase inhibition with omapatrilat in heart failure
43. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial
44. The vasopeptidase inhibitor, omapatrilat, has a favorable, pressure-independent effect on conduit vessel stiffness in patients with congestive heart failure
45. Angioedema due to ACE inhibitors: Increased risk in patients of African origin
46. Angiotensin II receptor blockers in patients with ACE inhibitor-induced angioedema
47. Angioedema due to angiotensin-converting enzyme inhibitors
48. Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema
49. Plasma bradykinin in angiooedema
50. Vasopeptidase inhibition and angio-oedema